SlideShare a Scribd company logo
1 of 22
Dialysis in Elderly
World Kidney Day 2014
Kalba
Dr. Muhamed AL Rohani, MD, FISN
Dialysis in elderly
Age:
Definition:
Calendar age
Biological age
Diseases
Genetic
Environment
Evaluation of elderly pt
Age
Comorbidity
Metal status
QoL
Life expectancy
Initiation of RRT
Vascular state
Compliance to RRT
Socio-economical state
Glomerulosclerosis
Atherosclerosis
Tubular atrophy
Interstitial fibrosis
Kidney aging:
Physiological renal aging (senescence):
Biopsy:
Drop of GFR
Hypertrophy and
hyperfunction of
unaffected nephrons
Decomposition off
other nephrons
The CKD Continuum
ESRDCKD
Diabetes
Hypertension
Obesity
CVD
Advanced CKD Care
• 30-20-10 & Timely Referral
• Promote Co-management and
Coordinated Care
• Multidisciplinary Team Care in
Nephrology
• Vascular Access management
• Case Management
– Diabetes
– Nutrition & Obesity
– Hypertension & CVD
• Treatment Options Education
RightStart
• At Renal Replacement
Therapy Start Reduce:
• Mortality
• Hospitalization
• CHF
• Transplant & Home
Therapies when
possible
• Support for:
• Permanent Access
• Nutrition
• Adequate Dialysis
• Anemia, Bone
Mgmt
PCP & Nephrology
Practice
• Public Awareness
• Screening of “At Risk”
patients
• Recommended evaluation
and monitoring of CKD
• Timely Referral to
Nephrology
• Education for Patients
RightReturn
• Reduce Repeat Hospitalization
• Medication Reconcilliation
• Integrated return to chronic
dialysis care
Early CKD Care impacts Late CKD Outcomes
CV Mortality in the General Population
and in Patients with Kidney Failure
AnnualMortality(%)
GP Male
GP Female
GP Black
GP White
Dialysis Male
Dialysis
Female
Dialysis
Black
Dialysis
White
Transplant
100
10
1
0.1
0.01
25–34 35–44 45–54 55–64 65–74 75–84 > 85
Age (years)
0.001
Sarnak, MJ et al. Hypertension 2003; 42: 1050-1065.
One year mortality 46%
Comprehensive geriatric assessment (CGA):
Geriatric assessment tools include:
Comorbidity (Charleson Comorbidity Index),
Functional status (Karnofsky scale, Katz and Barthel Index),
Physical performance (Timed Get up and Go test; timed walking speed),
Frailty testing (Frailty Phenotype4), cognition (MMSE, mini-cog),
Psychologic status (Geriatric Depression Scale),
Nutrition,
Medication review,
Urinary incontinence,
Visual/ hearing impairment,
Social support.
CGA can be followed serially and used in medical decision-making as
elderly patients and their families are faced with challenges such as
treatment for cancer, surgery, percutaneous gastrostomy tube
insertion, nursing home placement, withdrawal of intensive care unit
(ICU) care, and dialysis decisions.
DOPPS study:
46 – 55 % of pts aged ≥ 75yrs had coronary artery disease.
Myocardial dysfunction
LF low EF
LVH due to hypertension
Increase risk of hypotension during HD
Increase risk of pulmonary edema
25 – 30% cerebrovascular disease
Up to 50% had CHF and peripheral vascular dis.
40% of pts were unable to walk without assistance and 75% of the elderly has frailty
The repeated hypotension leads to hemodynamic instability and end-organ
hypoperfusion finishing woth cardiac events, cerebral dysfunction, and stroke.
Malnutrition – inflammation syndrome and loss of residual renal function
Higher rate of catheter use as vascular access with great risk of death
Poor AVF maturation
The problem of transport to HD-center
Geriatric Syndromes
Mental health disturbance:
Depression
Difficult to be diagnosed Heterogeneity
of causes (chronic infection,
malnutrition, malignancies,
electrolyte imbalance and drugs)
Dementia,
Delirium
Can be treated but only 10% treated,
Cognitive impairment
Disabilities,
Falls:
Fractures related to osteoporosis
Hip fractures
Mortality and morbidity
Multimorbidity management
Challenges of providing optimal care
QoL
Short life expectancy
Compliance to treatment
polypharmacy).
Number of drugs
Drug interaction
Categorization of pts based on estimated life expectancy and functional
level:
1- robust older people,: life expectancy ≥ 5 yrs, functionally independent, not needing help from caregivers.
2- frail older people : Life expectancy > 5 yrs, Significantly functional impairment requiring help from
caregivers
3- moderately demented older people: Life expectancy 2 – 10 yrs, May or may not be functionally impaired
4- end-of-life older people : Life expectancy < 2 yrs.
Four topics method for analysis of ethical problems in clinical medicine adapted to
the geriatric patient with CKD/ESRD
1. Medical indications for intervention
1. Beneficence and nonmalfeasance
2. Prognosis/benefits versus burdens
3. What is the functional age?
4. Is this patient frail?
5. What are the geriatric susceptibility
factors and survival data?
6. Base in the above:
1. Is the patient candidate for dialysis or
nondialytic treatment
2. Patient preferences respect for
autonomy
1. Established a “big picture” goals and
outcome
2. Explore patient`s personal narrative
3. Higher prevalence of cognitive
dysfunction and inability to make
decisions
4. Role of family
3. Quality of life
1. There is no universal metric for QoL
2. The QoL is a value judgment and
personal
3. There are some objective criteria
1. End-stage dementia
2. Cachexia
3. Advanced cancer
4. There is a significant symptom burden
4. Contextual features
1. Loyalty and fairness
2. Health resources and care
3. Family supportive
4. Conflicts between family members
5. Cultural or religious background
6. Conflict among the health care
providers
Copyright restrictions may apply.
Murtagh, F. E. M. et al. Nephrol. Dial. Transplant. 2007 22:1955-1962;
doi:10.1093/ndt/gfm153
(A) Kaplan–Meier
survival curves for
those with
ischaemic heart
disease, comparing
the dialysis and
conservative
groups (log rank
statistic 1.46, df 1,
P = 0.27).
(B) Kaplan–Meier
survival curves for
those without
ischaemic heart
disease, comparing
the dialysis and
conservative
groups (log rank
statistic 12.78, df 1,
P < 0.0001).
Survival of patients aged ≥75 years initiating dialysis in Australia between January 2002 and
December 2005 (Kaplan–Meier curves) with 95% CIs compared with survival of 75- and 80-
year-olds from the general Australian population [23].
Foote C et al. Nephrol. Dial. Transplant. 2012;ndt.gfs096
© The Author 2012. Published by Oxford University Press on behalf of ERA-EDTA. All rights
reserved. For Permissions, please e-mail: journals.permissions@oup.com
ESRDCKD
Diabetes
Hypertension
Obesity
CVD
atherosclerosis
Advanced CKD Care
• 30-20-10 & Timely Referral
• Promote Co-management and
Coordinated Care
• Multidisciplinary Team Care in
Nephrology
• Vascular Access management
• Case Management
– Diabetes
– Nutrition & Obesity
– Hypertension & CVD
• Treatment Options Education
RightStart
• At Renal Replacement
Therapy Start Reduce:
• Mortality
• Hospitalization
• CHF
• Transplant & Home
Therapies when
possible
• Support for:
• Permanent Access
• Nutrition
• Adequate Dialysis
• Anemia, Bone
Mgmt
PCP & Nephrology
Practice
• Public Awareness
• Screening of “At Risk”
patients
• Recommended evaluation
and monitoring of CKD
• Timely Referral to
Nephrology
• Education for Patients
RightReturn
• Reduce Repeat Hospitalization
• Medication Reconcilliation
• Integrated return to chronic
dialysis care
Mircroalbuminuria
GFR
Compensation
By unaffected
nephrons
Treatment
The CKD Continuum
Nephrology Care and CKD Outcomes
Control of Risk Factors for CKD
Progression and Adverse
Outcomes
Late Referral to Nephrology (all
patients were receiving Primary
Care)
Early Referral to Nephrology
Blood Pressure control
(to recommended goal)
39% 69%
HbA1c <7% 44% 82%
ACEI/ARB use
(for proteinuria >1 g/day)
36% 96%
Anemia treatment
(to recommended goal)
9% 52%
Nutritional Status Management 65% 81%
Fluid & Volume control 67% 83%
- Int J Clin Pract 2010, Herget-Rosenthal
Timely Referral Leads to Reduced Mortality
0%
10%
20%
30%
40%
< 1 month 1-4 mos > 4 mosOneYearMortalityRate
Timing of Referral to Nephrologist
(Time Prior to Start of Dialysis)
Impact of Timing of Referral to
Nephrologist on Mortality
Early Referral Late Referral
90 Day Mortality 3
3% 13%
6 Month Mortality 4
13% 31%
1 Year Mortality 5
6% 39%
1 Year Mortality 2 22% 41%
2 Year Mortality 6
56% 69%
2
5
In a Recent Study of 300 Medicare Beneficiaries,
the Risk of Death in the First Year on Dialysis
Was Reduced by 48% For Early Referral
Patients Compared to Late Referral Patients. 2
Several Other Studies Shown Below Confirm
This.
Transplantation:
Survival advantage in elderly pts,
Waiting list and age;
only 8% of pts on waiting list are elderly
Comorbidity preclude transplantation
Higher rate of complications:
Surgical
Infections
Malignancy
Conservative care :
Poor outcome
Multiple comorbidities on dialysis
In UK it is maximum management without
dialysis
In Australia 14% of elderly pts choose
conservative care
The care focus on
anemia,,
HTN,
CKD-MBD,
fluid status
Electrolytes imbalance
Acidosis
Some pts has longer life than those on dialysis,
QoL no comparison study,
NKF K/DOQI GUIDELINES:
Clinical Practice Guidelines and Clinical Practice
Recommendations
2006 Updates
Hemodialysis Adequacy
“…the recommended timing of dialysis therapy
initiation is a compromise designed to maximize
patient QOL by extending the dialysis-free period
while avoiding complications that will decrease the
length and quality of dialysis-assisted life.”
Quality of life during dialysis:
In UK dialysis population grew by 29% (2005 -2008)
in USA the rate is more
Median survival is 28.9 months
Quality of life:
In Canada within 6 months 30% required
community support or transfer to a
nursing home, and 22% still alive
after 1 yr.
Broadening Options for Long-term Dialysis in the Elderly (BOLDE): differences in quality of life on
peritoneal dialysis compared to haemodialysis for older patients
Conclusion:
The findings from this study support the greater use of PD in older people, and suggest that there may
be substantial under-utilisation in many centres in the UK. The fact that QOL may well be better on
PD due to its potentially lower intrusion into older peoples’ lives should influence the content of
predialysis education. Improved education would enable patients to choose dialysis modality based
on how it is going to affect their ability to maintain the aspects of life they value.
HD or PD ?
Patient RRT modalities:
Base on physicians and family
Patients mostly go to HD
Residual renal function
There is no clear evidence regarding the difference in
QoL for pts with HD and PD
AVF in elderly
Conflicting studies
No difference survival between
young and elderly
high rate of failure to mature
High rate of failure in 1st yr
Late referral
Failure of AVF to mature
85% of pts
2/3 continue > 3 months
The effect of atherosclerosis
The co-existence of heart failure
The maturity time for AVF
Increased risk of death
Factors affecting the outcome:
Hypertension
Arterial
stiffness
Vascular
calcification
sBP elevation
Renal artery
stenosis
RAASactivity
CKD –
MBD ?
Nitric
oxide
gloemrulosclerosis
Hypertension as risk factor
JNC 8:
In the general population aged 60
years, initiate pharmacologic treatment
to lower blood pressure (BP) at systolic
blood pressure (SBP)150 mmHg or
diastolic blood pressure (DBP)90mmHg
and treat to a goal SBP <150 mm Hg and
goal DBP <90 mm Hg.
(Strong Recommendation – Grade A)
In the population aged 18 years or older with CKD
and hypertension, initial antihypertensive treatment
should include an ACEI or ARBto improve kidney
outcomes. This applies to all CKD patients with
hypertension regardless of race or diabetes status.
Moderate Recommendation – Grade B
Withdrawal of Dialysis – Third Leading
Cause of Death
• Shared decision making
• Informed consent
• Estimate prognosis
• Advanced directives
• Time limited trials
• Palliative care
RPA/ASN
Dialysis in elderly patients wkd 2014

More Related Content

What's hot

chronic-kidney-disease-elderly.pptx
chronic-kidney-disease-elderly.pptxchronic-kidney-disease-elderly.pptx
chronic-kidney-disease-elderly.pptxHuda693686
 
Hypercalcemia (Practical Approach) - Dr. Gawad
Hypercalcemia (Practical Approach) - Dr. GawadHypercalcemia (Practical Approach) - Dr. Gawad
Hypercalcemia (Practical Approach) - Dr. GawadNephroTube - Dr.Gawad
 
Ckd mbd - dr. hanan moustafa
Ckd mbd - dr. hanan moustafaCkd mbd - dr. hanan moustafa
Ckd mbd - dr. hanan moustafaFarragBahbah
 
Anemia management in CKD (ESA Therapy) - Dr. Gawad
Anemia management in CKD (ESA Therapy) - Dr. GawadAnemia management in CKD (ESA Therapy) - Dr. Gawad
Anemia management in CKD (ESA Therapy) - Dr. GawadNephroTube - Dr.Gawad
 
CKD MBD - Drug Related Issues - Dr. Gawad
CKD MBD - Drug Related Issues - Dr. GawadCKD MBD - Drug Related Issues - Dr. Gawad
CKD MBD - Drug Related Issues - Dr. GawadNephroTube - Dr.Gawad
 
CKD MBD - Think Outside The Box - Case Scenarios Snapshots - Dr. Gawad
CKD MBD - Think Outside The Box - Case Scenarios Snapshots  - Dr. GawadCKD MBD - Think Outside The Box - Case Scenarios Snapshots  - Dr. Gawad
CKD MBD - Think Outside The Box - Case Scenarios Snapshots - Dr. GawadNephroTube - Dr.Gawad
 
CKD Mineral Bone Disorder (CKD-MBD) - Dr. Gawad
CKD Mineral Bone Disorder (CKD-MBD) - Dr. GawadCKD Mineral Bone Disorder (CKD-MBD) - Dr. Gawad
CKD Mineral Bone Disorder (CKD-MBD) - Dr. GawadNephroTube - Dr.Gawad
 
Dry Weight Dr Rosna
Dry Weight Dr RosnaDry Weight Dr Rosna
Dry Weight Dr Rosnaedwinchowyw
 
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. GawadDrug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. GawadNephroTube - Dr.Gawad
 
Ckd mbd guideline
Ckd mbd guidelineCkd mbd guideline
Ckd mbd guidelinedrsam123
 
Diagnosis, Evaluation, Prevention and Treatment of CKD-MBD
Diagnosis, Evaluation, Prevention and Treatment of CKD-MBDDiagnosis, Evaluation, Prevention and Treatment of CKD-MBD
Diagnosis, Evaluation, Prevention and Treatment of CKD-MBDAbdullah Ansari
 
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. Gawad
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. GawadDiabetes Mellitus Management in CKD (Clinical Tips) - Dr. Gawad
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. GawadNephroTube - Dr.Gawad
 
Anemia in ckd patients
Anemia in ckd patientsAnemia in ckd patients
Anemia in ckd patientsFarragBahbah
 
Anemia in CKD
Anemia in CKDAnemia in CKD
Anemia in CKDSariu Ali
 
Ckd mbd where are we
Ckd mbd where are weCkd mbd where are we
Ckd mbd where are weFarragBahbah
 
Chronic Kidney Disease (CKD) - At a Glance - Dr. Gawad
Chronic Kidney Disease (CKD) - At a Glance - Dr. GawadChronic Kidney Disease (CKD) - At a Glance - Dr. Gawad
Chronic Kidney Disease (CKD) - At a Glance - Dr. GawadNephroTube - Dr.Gawad
 
Asymptomatic Hyperuricemia with CKD (To Treat or Not To Treat) - Dr. Gawad
Asymptomatic Hyperuricemia with CKD (To Treat or Not To Treat) - Dr. GawadAsymptomatic Hyperuricemia with CKD (To Treat or Not To Treat) - Dr. Gawad
Asymptomatic Hyperuricemia with CKD (To Treat or Not To Treat) - Dr. GawadNephroTube - Dr.Gawad
 
CKD (Pathogensis and Progression) - Dr. Gawad
CKD (Pathogensis and Progression) - Dr. GawadCKD (Pathogensis and Progression) - Dr. Gawad
CKD (Pathogensis and Progression) - Dr. GawadNephroTube - Dr.Gawad
 

What's hot (20)

chronic-kidney-disease-elderly.pptx
chronic-kidney-disease-elderly.pptxchronic-kidney-disease-elderly.pptx
chronic-kidney-disease-elderly.pptx
 
Hypercalcemia (Practical Approach) - Dr. Gawad
Hypercalcemia (Practical Approach) - Dr. GawadHypercalcemia (Practical Approach) - Dr. Gawad
Hypercalcemia (Practical Approach) - Dr. Gawad
 
Ckd mbd - dr. hanan moustafa
Ckd mbd - dr. hanan moustafaCkd mbd - dr. hanan moustafa
Ckd mbd - dr. hanan moustafa
 
Anemia management in CKD (ESA Therapy) - Dr. Gawad
Anemia management in CKD (ESA Therapy) - Dr. GawadAnemia management in CKD (ESA Therapy) - Dr. Gawad
Anemia management in CKD (ESA Therapy) - Dr. Gawad
 
CKD MBD - Drug Related Issues - Dr. Gawad
CKD MBD - Drug Related Issues - Dr. GawadCKD MBD - Drug Related Issues - Dr. Gawad
CKD MBD - Drug Related Issues - Dr. Gawad
 
CKD MBD - Think Outside The Box - Case Scenarios Snapshots - Dr. Gawad
CKD MBD - Think Outside The Box - Case Scenarios Snapshots  - Dr. GawadCKD MBD - Think Outside The Box - Case Scenarios Snapshots  - Dr. Gawad
CKD MBD - Think Outside The Box - Case Scenarios Snapshots - Dr. Gawad
 
CKD Mineral Bone Disorder (CKD-MBD) - Dr. Gawad
CKD Mineral Bone Disorder (CKD-MBD) - Dr. GawadCKD Mineral Bone Disorder (CKD-MBD) - Dr. Gawad
CKD Mineral Bone Disorder (CKD-MBD) - Dr. Gawad
 
Dry Weight Dr Rosna
Dry Weight Dr RosnaDry Weight Dr Rosna
Dry Weight Dr Rosna
 
CRRT in ICU - AKI - Dr. Gawad
CRRT in ICU - AKI - Dr. GawadCRRT in ICU - AKI - Dr. Gawad
CRRT in ICU - AKI - Dr. Gawad
 
Dkd master class
Dkd master class Dkd master class
Dkd master class
 
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. GawadDrug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
 
Ckd mbd guideline
Ckd mbd guidelineCkd mbd guideline
Ckd mbd guideline
 
Diagnosis, Evaluation, Prevention and Treatment of CKD-MBD
Diagnosis, Evaluation, Prevention and Treatment of CKD-MBDDiagnosis, Evaluation, Prevention and Treatment of CKD-MBD
Diagnosis, Evaluation, Prevention and Treatment of CKD-MBD
 
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. Gawad
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. GawadDiabetes Mellitus Management in CKD (Clinical Tips) - Dr. Gawad
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. Gawad
 
Anemia in ckd patients
Anemia in ckd patientsAnemia in ckd patients
Anemia in ckd patients
 
Anemia in CKD
Anemia in CKDAnemia in CKD
Anemia in CKD
 
Ckd mbd where are we
Ckd mbd where are weCkd mbd where are we
Ckd mbd where are we
 
Chronic Kidney Disease (CKD) - At a Glance - Dr. Gawad
Chronic Kidney Disease (CKD) - At a Glance - Dr. GawadChronic Kidney Disease (CKD) - At a Glance - Dr. Gawad
Chronic Kidney Disease (CKD) - At a Glance - Dr. Gawad
 
Asymptomatic Hyperuricemia with CKD (To Treat or Not To Treat) - Dr. Gawad
Asymptomatic Hyperuricemia with CKD (To Treat or Not To Treat) - Dr. GawadAsymptomatic Hyperuricemia with CKD (To Treat or Not To Treat) - Dr. Gawad
Asymptomatic Hyperuricemia with CKD (To Treat or Not To Treat) - Dr. Gawad
 
CKD (Pathogensis and Progression) - Dr. Gawad
CKD (Pathogensis and Progression) - Dr. GawadCKD (Pathogensis and Progression) - Dr. Gawad
CKD (Pathogensis and Progression) - Dr. Gawad
 

Viewers also liked

Complications of hemodialysis
Complications of hemodialysisComplications of hemodialysis
Complications of hemodialysisReynel Dan
 
complications of HD case presentation
complications of HD case presentationcomplications of HD case presentation
complications of HD case presentationDr. Abrar Ali Katpar
 
Hemodialysis Dr. Sanaa Kamal
Hemodialysis Dr. Sanaa KamalHemodialysis Dr. Sanaa Kamal
Hemodialysis Dr. Sanaa Kamalsubauday
 
Nutritional and metabolic considerations in elderly dialysis patients
Nutritional and metabolic considerations in elderly dialysis patientsNutritional and metabolic considerations in elderly dialysis patients
Nutritional and metabolic considerations in elderly dialysis patientsMarc Evans Abat
 
Nursing Care of Patient on Dialysis
Nursing Care  of Patient on DialysisNursing Care  of Patient on Dialysis
Nursing Care of Patient on DialysisShanta Peter
 

Viewers also liked (10)

Dialysis unit
Dialysis unitDialysis unit
Dialysis unit
 
Complications of hemodialysis
Complications of hemodialysisComplications of hemodialysis
Complications of hemodialysis
 
Kidney dialysis
Kidney dialysisKidney dialysis
Kidney dialysis
 
complications of HD case presentation
complications of HD case presentationcomplications of HD case presentation
complications of HD case presentation
 
Hemodialysis Dr. Sanaa Kamal
Hemodialysis Dr. Sanaa KamalHemodialysis Dr. Sanaa Kamal
Hemodialysis Dr. Sanaa Kamal
 
Urine Under Microscope
Urine Under MicroscopeUrine Under Microscope
Urine Under Microscope
 
Nutritional and metabolic considerations in elderly dialysis patients
Nutritional and metabolic considerations in elderly dialysis patientsNutritional and metabolic considerations in elderly dialysis patients
Nutritional and metabolic considerations in elderly dialysis patients
 
Nursing Care of Patient on Dialysis
Nursing Care  of Patient on DialysisNursing Care  of Patient on Dialysis
Nursing Care of Patient on Dialysis
 
Urine analysis
Urine analysisUrine analysis
Urine analysis
 
Dialysis
DialysisDialysis
Dialysis
 

Similar to Dialysis in elderly patients wkd 2014

Concept of a ‘CKD Clinic’
Concept of a ‘CKD Clinic’Concept of a ‘CKD Clinic’
Concept of a ‘CKD Clinic’drsanjaymaitra
 
Efficacy of Dietary Intervention in END STAGE RENAL DISEASE
Efficacy of Dietary Intervention in END STAGE RENAL DISEASEEfficacy of Dietary Intervention in END STAGE RENAL DISEASE
Efficacy of Dietary Intervention in END STAGE RENAL DISEASEJunaid Nazar
 
Medical Director Responsibilities and Hospice Eligibility and Recertification
Medical Director Responsibilities and Hospice Eligibility and RecertificationMedical Director Responsibilities and Hospice Eligibility and Recertification
Medical Director Responsibilities and Hospice Eligibility and RecertificationTerri Hanlon Baker
 
Indications of peritoneal dialysis
Indications of peritoneal dialysisIndications of peritoneal dialysis
Indications of peritoneal dialysisMuhammad Mohsin Riaz
 
Chronic kidney disease: a quiet revolution in nephrology
Chronic kidney disease: a quiet revolution in nephrology Chronic kidney disease: a quiet revolution in nephrology
Chronic kidney disease: a quiet revolution in nephrology Christos Argyropoulos
 
Dm &amp; liver
Dm &amp;  liverDm &amp;  liver
Dm &amp; liveralaa wafa
 
Slowing Progression of Chronic Kidney Disease Through Value-Based Care
Slowing Progression of Chronic Kidney Disease Through Value-Based CareSlowing Progression of Chronic Kidney Disease Through Value-Based Care
Slowing Progression of Chronic Kidney Disease Through Value-Based Carei3 Health
 
Revolutionizing Renal Care With Predictive Analytics for CKD
Revolutionizing Renal Care With Predictive Analytics for CKDRevolutionizing Renal Care With Predictive Analytics for CKD
Revolutionizing Renal Care With Predictive Analytics for CKDViewics
 
Running head illness and disease managementillness and dise
Running head illness and disease managementillness and diseRunning head illness and disease managementillness and dise
Running head illness and disease managementillness and disearyan532920
 
Ckd prevention
Ckd preventionCkd prevention
Ckd preventiondarsh 1980
 
KIDNEY TRANSPLANTATION PREPARATION AND CONSENTING
KIDNEY TRANSPLANTATION PREPARATION AND CONSENTINGKIDNEY TRANSPLANTATION PREPARATION AND CONSENTING
KIDNEY TRANSPLANTATION PREPARATION AND CONSENTINGDr Mayank Mohan Agarwal
 
Marginal Donors/Expanded Criteria Donors Kidneys
Marginal Donors/Expanded Criteria Donors KidneysMarginal Donors/Expanded Criteria Donors Kidneys
Marginal Donors/Expanded Criteria Donors KidneysAbdullah Ansari
 
Renal and Diabetes Continuing Education Presentation
Renal and Diabetes Continuing Education PresentationRenal and Diabetes Continuing Education Presentation
Renal and Diabetes Continuing Education PresentationAlisa McAleer
 
Συχνότερα χρόνια νοσήματα, καταστάσεις υγείας, συχνότερα συμπτώματα στην κοιν...
Συχνότερα χρόνια νοσήματα, καταστάσεις υγείας, συχνότερα συμπτώματα στην κοιν...Συχνότερα χρόνια νοσήματα, καταστάσεις υγείας, συχνότερα συμπτώματα στην κοιν...
Συχνότερα χρόνια νοσήματα, καταστάσεις υγείας, συχνότερα συμπτώματα στην κοιν...Evangelos Fragkoulis
 
Hospice Basics and Benefits | VITAS Healthcare
Hospice Basics and Benefits | VITAS HealthcareHospice Basics and Benefits | VITAS Healthcare
Hospice Basics and Benefits | VITAS HealthcareVITAS Healthcare
 
American Association of Clinical Endocrinology Clinical Practice [Autosaved]....
American Association of Clinical Endocrinology Clinical Practice [Autosaved]....American Association of Clinical Endocrinology Clinical Practice [Autosaved]....
American Association of Clinical Endocrinology Clinical Practice [Autosaved]....vardhini14
 
Management of diabetes in elderly
Management of diabetes in elderlyManagement of diabetes in elderly
Management of diabetes in elderlyAditya Sarin
 
Chronic Kidney Disease Nursing case presentation
Chronic Kidney Disease Nursing case presentationChronic Kidney Disease Nursing case presentation
Chronic Kidney Disease Nursing case presentationChinmayi24
 
4 5764843123465258464
4 57648431234652584644 5764843123465258464
4 5764843123465258464amarewoldie1
 

Similar to Dialysis in elderly patients wkd 2014 (20)

Concept of a ‘CKD Clinic’
Concept of a ‘CKD Clinic’Concept of a ‘CKD Clinic’
Concept of a ‘CKD Clinic’
 
Efficacy of Dietary Intervention in END STAGE RENAL DISEASE
Efficacy of Dietary Intervention in END STAGE RENAL DISEASEEfficacy of Dietary Intervention in END STAGE RENAL DISEASE
Efficacy of Dietary Intervention in END STAGE RENAL DISEASE
 
Hd o dp en ancianos fragiles
Hd o dp en ancianos fragilesHd o dp en ancianos fragiles
Hd o dp en ancianos fragiles
 
Medical Director Responsibilities and Hospice Eligibility and Recertification
Medical Director Responsibilities and Hospice Eligibility and RecertificationMedical Director Responsibilities and Hospice Eligibility and Recertification
Medical Director Responsibilities and Hospice Eligibility and Recertification
 
Indications of peritoneal dialysis
Indications of peritoneal dialysisIndications of peritoneal dialysis
Indications of peritoneal dialysis
 
Chronic kidney disease: a quiet revolution in nephrology
Chronic kidney disease: a quiet revolution in nephrology Chronic kidney disease: a quiet revolution in nephrology
Chronic kidney disease: a quiet revolution in nephrology
 
Dm &amp; liver
Dm &amp;  liverDm &amp;  liver
Dm &amp; liver
 
Slowing Progression of Chronic Kidney Disease Through Value-Based Care
Slowing Progression of Chronic Kidney Disease Through Value-Based CareSlowing Progression of Chronic Kidney Disease Through Value-Based Care
Slowing Progression of Chronic Kidney Disease Through Value-Based Care
 
Revolutionizing Renal Care With Predictive Analytics for CKD
Revolutionizing Renal Care With Predictive Analytics for CKDRevolutionizing Renal Care With Predictive Analytics for CKD
Revolutionizing Renal Care With Predictive Analytics for CKD
 
Running head illness and disease managementillness and dise
Running head illness and disease managementillness and diseRunning head illness and disease managementillness and dise
Running head illness and disease managementillness and dise
 
Ckd prevention
Ckd preventionCkd prevention
Ckd prevention
 
KIDNEY TRANSPLANTATION PREPARATION AND CONSENTING
KIDNEY TRANSPLANTATION PREPARATION AND CONSENTINGKIDNEY TRANSPLANTATION PREPARATION AND CONSENTING
KIDNEY TRANSPLANTATION PREPARATION AND CONSENTING
 
Marginal Donors/Expanded Criteria Donors Kidneys
Marginal Donors/Expanded Criteria Donors KidneysMarginal Donors/Expanded Criteria Donors Kidneys
Marginal Donors/Expanded Criteria Donors Kidneys
 
Renal and Diabetes Continuing Education Presentation
Renal and Diabetes Continuing Education PresentationRenal and Diabetes Continuing Education Presentation
Renal and Diabetes Continuing Education Presentation
 
Συχνότερα χρόνια νοσήματα, καταστάσεις υγείας, συχνότερα συμπτώματα στην κοιν...
Συχνότερα χρόνια νοσήματα, καταστάσεις υγείας, συχνότερα συμπτώματα στην κοιν...Συχνότερα χρόνια νοσήματα, καταστάσεις υγείας, συχνότερα συμπτώματα στην κοιν...
Συχνότερα χρόνια νοσήματα, καταστάσεις υγείας, συχνότερα συμπτώματα στην κοιν...
 
Hospice Basics and Benefits | VITAS Healthcare
Hospice Basics and Benefits | VITAS HealthcareHospice Basics and Benefits | VITAS Healthcare
Hospice Basics and Benefits | VITAS Healthcare
 
American Association of Clinical Endocrinology Clinical Practice [Autosaved]....
American Association of Clinical Endocrinology Clinical Practice [Autosaved]....American Association of Clinical Endocrinology Clinical Practice [Autosaved]....
American Association of Clinical Endocrinology Clinical Practice [Autosaved]....
 
Management of diabetes in elderly
Management of diabetes in elderlyManagement of diabetes in elderly
Management of diabetes in elderly
 
Chronic Kidney Disease Nursing case presentation
Chronic Kidney Disease Nursing case presentationChronic Kidney Disease Nursing case presentation
Chronic Kidney Disease Nursing case presentation
 
4 5764843123465258464
4 57648431234652584644 5764843123465258464
4 5764843123465258464
 

More from Muhamed Al Rohani

More from Muhamed Al Rohani (9)

hemodialysis catheter infection
hemodialysis catheter infectionhemodialysis catheter infection
hemodialysis catheter infection
 
rhabdomyolysis 2016
rhabdomyolysis 2016rhabdomyolysis 2016
rhabdomyolysis 2016
 
Aki icu
Aki icuAki icu
Aki icu
 
The organs damages as side effects of NSAIDs
The organs damages as side effects of NSAIDsThe organs damages as side effects of NSAIDs
The organs damages as side effects of NSAIDs
 
Hypertension conbinsation therapy 2014
Hypertension conbinsation therapy 2014Hypertension conbinsation therapy 2014
Hypertension conbinsation therapy 2014
 
Htn combination thrapy f
Htn combination thrapy fHtn combination thrapy f
Htn combination thrapy f
 
pathophysiology and therapy of diabetic nephropathy
pathophysiology and therapy of diabetic nephropathypathophysiology and therapy of diabetic nephropathy
pathophysiology and therapy of diabetic nephropathy
 
Dkd new look
Dkd new lookDkd new look
Dkd new look
 
Nephrotoxicity eman 2013
Nephrotoxicity eman 2013Nephrotoxicity eman 2013
Nephrotoxicity eman 2013
 

Dialysis in elderly patients wkd 2014

  • 1. Dialysis in Elderly World Kidney Day 2014 Kalba Dr. Muhamed AL Rohani, MD, FISN
  • 2. Dialysis in elderly Age: Definition: Calendar age Biological age Diseases Genetic Environment Evaluation of elderly pt Age Comorbidity Metal status QoL Life expectancy Initiation of RRT Vascular state Compliance to RRT Socio-economical state
  • 3. Glomerulosclerosis Atherosclerosis Tubular atrophy Interstitial fibrosis Kidney aging: Physiological renal aging (senescence): Biopsy: Drop of GFR Hypertrophy and hyperfunction of unaffected nephrons Decomposition off other nephrons
  • 4. The CKD Continuum ESRDCKD Diabetes Hypertension Obesity CVD Advanced CKD Care • 30-20-10 & Timely Referral • Promote Co-management and Coordinated Care • Multidisciplinary Team Care in Nephrology • Vascular Access management • Case Management – Diabetes – Nutrition & Obesity – Hypertension & CVD • Treatment Options Education RightStart • At Renal Replacement Therapy Start Reduce: • Mortality • Hospitalization • CHF • Transplant & Home Therapies when possible • Support for: • Permanent Access • Nutrition • Adequate Dialysis • Anemia, Bone Mgmt PCP & Nephrology Practice • Public Awareness • Screening of “At Risk” patients • Recommended evaluation and monitoring of CKD • Timely Referral to Nephrology • Education for Patients RightReturn • Reduce Repeat Hospitalization • Medication Reconcilliation • Integrated return to chronic dialysis care Early CKD Care impacts Late CKD Outcomes
  • 5. CV Mortality in the General Population and in Patients with Kidney Failure AnnualMortality(%) GP Male GP Female GP Black GP White Dialysis Male Dialysis Female Dialysis Black Dialysis White Transplant 100 10 1 0.1 0.01 25–34 35–44 45–54 55–64 65–74 75–84 > 85 Age (years) 0.001 Sarnak, MJ et al. Hypertension 2003; 42: 1050-1065. One year mortality 46%
  • 6. Comprehensive geriatric assessment (CGA): Geriatric assessment tools include: Comorbidity (Charleson Comorbidity Index), Functional status (Karnofsky scale, Katz and Barthel Index), Physical performance (Timed Get up and Go test; timed walking speed), Frailty testing (Frailty Phenotype4), cognition (MMSE, mini-cog), Psychologic status (Geriatric Depression Scale), Nutrition, Medication review, Urinary incontinence, Visual/ hearing impairment, Social support. CGA can be followed serially and used in medical decision-making as elderly patients and their families are faced with challenges such as treatment for cancer, surgery, percutaneous gastrostomy tube insertion, nursing home placement, withdrawal of intensive care unit (ICU) care, and dialysis decisions.
  • 7. DOPPS study: 46 – 55 % of pts aged ≥ 75yrs had coronary artery disease. Myocardial dysfunction LF low EF LVH due to hypertension Increase risk of hypotension during HD Increase risk of pulmonary edema 25 – 30% cerebrovascular disease Up to 50% had CHF and peripheral vascular dis. 40% of pts were unable to walk without assistance and 75% of the elderly has frailty The repeated hypotension leads to hemodynamic instability and end-organ hypoperfusion finishing woth cardiac events, cerebral dysfunction, and stroke. Malnutrition – inflammation syndrome and loss of residual renal function Higher rate of catheter use as vascular access with great risk of death Poor AVF maturation The problem of transport to HD-center
  • 8. Geriatric Syndromes Mental health disturbance: Depression Difficult to be diagnosed Heterogeneity of causes (chronic infection, malnutrition, malignancies, electrolyte imbalance and drugs) Dementia, Delirium Can be treated but only 10% treated, Cognitive impairment Disabilities, Falls: Fractures related to osteoporosis Hip fractures Mortality and morbidity Multimorbidity management Challenges of providing optimal care QoL Short life expectancy Compliance to treatment polypharmacy). Number of drugs Drug interaction Categorization of pts based on estimated life expectancy and functional level: 1- robust older people,: life expectancy ≥ 5 yrs, functionally independent, not needing help from caregivers. 2- frail older people : Life expectancy > 5 yrs, Significantly functional impairment requiring help from caregivers 3- moderately demented older people: Life expectancy 2 – 10 yrs, May or may not be functionally impaired 4- end-of-life older people : Life expectancy < 2 yrs.
  • 9. Four topics method for analysis of ethical problems in clinical medicine adapted to the geriatric patient with CKD/ESRD 1. Medical indications for intervention 1. Beneficence and nonmalfeasance 2. Prognosis/benefits versus burdens 3. What is the functional age? 4. Is this patient frail? 5. What are the geriatric susceptibility factors and survival data? 6. Base in the above: 1. Is the patient candidate for dialysis or nondialytic treatment 2. Patient preferences respect for autonomy 1. Established a “big picture” goals and outcome 2. Explore patient`s personal narrative 3. Higher prevalence of cognitive dysfunction and inability to make decisions 4. Role of family 3. Quality of life 1. There is no universal metric for QoL 2. The QoL is a value judgment and personal 3. There are some objective criteria 1. End-stage dementia 2. Cachexia 3. Advanced cancer 4. There is a significant symptom burden 4. Contextual features 1. Loyalty and fairness 2. Health resources and care 3. Family supportive 4. Conflicts between family members 5. Cultural or religious background 6. Conflict among the health care providers
  • 10. Copyright restrictions may apply. Murtagh, F. E. M. et al. Nephrol. Dial. Transplant. 2007 22:1955-1962; doi:10.1093/ndt/gfm153 (A) Kaplan–Meier survival curves for those with ischaemic heart disease, comparing the dialysis and conservative groups (log rank statistic 1.46, df 1, P = 0.27). (B) Kaplan–Meier survival curves for those without ischaemic heart disease, comparing the dialysis and conservative groups (log rank statistic 12.78, df 1, P < 0.0001).
  • 11. Survival of patients aged ≥75 years initiating dialysis in Australia between January 2002 and December 2005 (Kaplan–Meier curves) with 95% CIs compared with survival of 75- and 80- year-olds from the general Australian population [23]. Foote C et al. Nephrol. Dial. Transplant. 2012;ndt.gfs096 © The Author 2012. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com
  • 12. ESRDCKD Diabetes Hypertension Obesity CVD atherosclerosis Advanced CKD Care • 30-20-10 & Timely Referral • Promote Co-management and Coordinated Care • Multidisciplinary Team Care in Nephrology • Vascular Access management • Case Management – Diabetes – Nutrition & Obesity – Hypertension & CVD • Treatment Options Education RightStart • At Renal Replacement Therapy Start Reduce: • Mortality • Hospitalization • CHF • Transplant & Home Therapies when possible • Support for: • Permanent Access • Nutrition • Adequate Dialysis • Anemia, Bone Mgmt PCP & Nephrology Practice • Public Awareness • Screening of “At Risk” patients • Recommended evaluation and monitoring of CKD • Timely Referral to Nephrology • Education for Patients RightReturn • Reduce Repeat Hospitalization • Medication Reconcilliation • Integrated return to chronic dialysis care Mircroalbuminuria GFR Compensation By unaffected nephrons Treatment The CKD Continuum
  • 13. Nephrology Care and CKD Outcomes Control of Risk Factors for CKD Progression and Adverse Outcomes Late Referral to Nephrology (all patients were receiving Primary Care) Early Referral to Nephrology Blood Pressure control (to recommended goal) 39% 69% HbA1c <7% 44% 82% ACEI/ARB use (for proteinuria >1 g/day) 36% 96% Anemia treatment (to recommended goal) 9% 52% Nutritional Status Management 65% 81% Fluid & Volume control 67% 83% - Int J Clin Pract 2010, Herget-Rosenthal
  • 14. Timely Referral Leads to Reduced Mortality 0% 10% 20% 30% 40% < 1 month 1-4 mos > 4 mosOneYearMortalityRate Timing of Referral to Nephrologist (Time Prior to Start of Dialysis) Impact of Timing of Referral to Nephrologist on Mortality Early Referral Late Referral 90 Day Mortality 3 3% 13% 6 Month Mortality 4 13% 31% 1 Year Mortality 5 6% 39% 1 Year Mortality 2 22% 41% 2 Year Mortality 6 56% 69% 2 5 In a Recent Study of 300 Medicare Beneficiaries, the Risk of Death in the First Year on Dialysis Was Reduced by 48% For Early Referral Patients Compared to Late Referral Patients. 2 Several Other Studies Shown Below Confirm This.
  • 15. Transplantation: Survival advantage in elderly pts, Waiting list and age; only 8% of pts on waiting list are elderly Comorbidity preclude transplantation Higher rate of complications: Surgical Infections Malignancy Conservative care : Poor outcome Multiple comorbidities on dialysis In UK it is maximum management without dialysis In Australia 14% of elderly pts choose conservative care The care focus on anemia,, HTN, CKD-MBD, fluid status Electrolytes imbalance Acidosis Some pts has longer life than those on dialysis, QoL no comparison study,
  • 16. NKF K/DOQI GUIDELINES: Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis Adequacy “…the recommended timing of dialysis therapy initiation is a compromise designed to maximize patient QOL by extending the dialysis-free period while avoiding complications that will decrease the length and quality of dialysis-assisted life.”
  • 17. Quality of life during dialysis: In UK dialysis population grew by 29% (2005 -2008) in USA the rate is more Median survival is 28.9 months Quality of life: In Canada within 6 months 30% required community support or transfer to a nursing home, and 22% still alive after 1 yr. Broadening Options for Long-term Dialysis in the Elderly (BOLDE): differences in quality of life on peritoneal dialysis compared to haemodialysis for older patients Conclusion: The findings from this study support the greater use of PD in older people, and suggest that there may be substantial under-utilisation in many centres in the UK. The fact that QOL may well be better on PD due to its potentially lower intrusion into older peoples’ lives should influence the content of predialysis education. Improved education would enable patients to choose dialysis modality based on how it is going to affect their ability to maintain the aspects of life they value. HD or PD ? Patient RRT modalities: Base on physicians and family Patients mostly go to HD Residual renal function There is no clear evidence regarding the difference in QoL for pts with HD and PD
  • 18. AVF in elderly Conflicting studies No difference survival between young and elderly high rate of failure to mature High rate of failure in 1st yr Late referral Failure of AVF to mature 85% of pts 2/3 continue > 3 months The effect of atherosclerosis The co-existence of heart failure The maturity time for AVF Increased risk of death Factors affecting the outcome:
  • 19.
  • 20. Hypertension Arterial stiffness Vascular calcification sBP elevation Renal artery stenosis RAASactivity CKD – MBD ? Nitric oxide gloemrulosclerosis Hypertension as risk factor JNC 8: In the general population aged 60 years, initiate pharmacologic treatment to lower blood pressure (BP) at systolic blood pressure (SBP)150 mmHg or diastolic blood pressure (DBP)90mmHg and treat to a goal SBP <150 mm Hg and goal DBP <90 mm Hg. (Strong Recommendation – Grade A) In the population aged 18 years or older with CKD and hypertension, initial antihypertensive treatment should include an ACEI or ARBto improve kidney outcomes. This applies to all CKD patients with hypertension regardless of race or diabetes status. Moderate Recommendation – Grade B
  • 21. Withdrawal of Dialysis – Third Leading Cause of Death • Shared decision making • Informed consent • Estimate prognosis • Advanced directives • Time limited trials • Palliative care RPA/ASN